Impact Factor
3.20
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.70
282 total citations
h5-index
21
h5 depth signal
Cited share
73.3%
77 of 105
Total citations
282
Citation footprint
Metric signal
2.39
External metric anchor
Self-citation
4.6%
13 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
240
India
64
United States
54
Italy
30
Iran
27
Citing Fields of Research
Oncology
145
Cancer & Development
113
Cancer, Autophagy & Apoptosis
90
Cancer Drugs
65
Phytochemicals
54
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
855
Articles tracked across the journal lifetime
Indexed publication set
105
77 cited publications
Last 12 months
91
7.6 publications/month
Open access share
2.2%
2 OA publications in the last year
Leading citing country
China
240 citing publications
Leading citing field
Oncology
145 citing publications
Latest tracked publication
30 September 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan. 2006-
v1n1, Jan. 2006-
Research Focus & Classification
Indexed Subjects
Cancer & Development
Oncology
Immunology
Cancer, Autophagy & Apoptosis
Lung Cancer
Phytochemicals
Broad Categories
Drug Therapy
Neoplasms
Pharmacology
Cancer, Autophagy & Apoptosis
Noncoding RNA
Phytochemicals
Cancer & Development
Immunology
Lung Cancer
Lymphomas
MeSH Descriptors
Antineoplastic Agents
Neoplasms
Patents as Topic
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.2174/0115748928508182260928045722
Open DOI
Anisodine Activates SIK1 to Drive RIPK1-dependent Necroptosis in TNBC
Introduction: Triple-Negative Breast Cancer (TNBC) has limited targeted therapeutic options. SIK1 is a tumor-suppressive kinase in breast cancer, but pharmacological SIK1 activators remain poorly defined. Although recent anticancer paten...
02
DOI 10.2174/0115748928509831260914140853
Open DOI
Carvacrol-enriched Multi-component Oil Reduces Tumour Growth in a Triple-negative Breast Cancer Xenograft Model
Introduction: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with poor prognosis and limited targeted treatment options. Natural multicomponent formulations have emerged as promising complementary ...
03
DOI 10.2174/0115748928516880260914053850
Open DOI
Kushenol E Attenuates AOM/DSS-induced Colorectal Tumorigenesis in Mice, Inhibits Proliferation, and Induces Apoptosis in HT-29 Colorectal Cancer Cells
Introduction: Kushenol E is a prenylated flavonoid derived from Sophora flavescens. Although preliminary studies have suggested that Kushenol E possesses anticancer activity, its effects and molecular mechanisms in Colorectal Cancer (CRC...
04
DOI 10.2174/157489282105260916150055
Open DOI
Patent Selections
05
DOI 10.2174/0115748928511781260901094143
Open DOI
Plant-derived Alkaloids as Emerging Therapeutic Agents for Colorectal Cancer: Molecular Mechanisms and Translational Perspectives
Introduction: Plant-derived alkaloids have attracted growing attention in Colorectal Cancer (CRC) research because of their diverse biological activities and ability to regulate multiple oncogenic pathways. CRC remains a major cause of c...
06
DOI 10.2174/157489282104260914170420
Open DOI
Patent Selections
07
DOI 10.2174/0115748928453880260827093711
Open DOI
Targeted Therapeutics in Breast Cancer: Promise, Progress, and the Challenge of Triple-negative Subtype
Introduction: Breast cancer is the most common cancer that affects women globally, with several molecular subtypes defined by hormone and growth factor receptor expression. While advances in understanding the biology of these subtypes ha...
08
DOI 10.2174/0115748928447973260824065600
Open DOI
Exploring New Frontiers in Osteosarcoma Treatment: Clinical Trial Insights
Introduction: Osteosarcoma (OS) is a common bone malignancy in adolescents and older adults and typically develops in the long bones. Outcomes in advanced cases remain poor despite the use of chemotherapeutic drugs like doxorubicin, meth...
09
DOI 10.2174/0115748928447033260824144017
Open DOI
Antineoplastic Drugs: Research Progress of Immune Checkpoint CD47 Inhibitors
Immunotherapy using immune checkpoint inhibitors represents a breakthrough in cancer treatment. The overexpressed CD47 on tumor surfaces functions as a 'don’t eat me' signal by binding to signal regulatory protein alpha (SIRPα) on macrop...
10
DOI 10.2174/0115748928472096260821102954
Open DOI
Glypican-1 in Rhabdomyosarcoma: A Multi-omics Exploration of a Targetable Biomarker
Introduction: Glypican-1 (GPC1), a heparan sulfate proteoglycan found on the cell surface, has been associated with carcinogenesis and chemoresistance in several malignancies. However, its function in rhabdomyosarcoma remains poorly unde...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.